{"id":"W2568149294","doi":"10.1016/j.jtho.2016.11.445","title":"MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; University of Calgary; Hôpital Notre-Dame; Queen's University; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Durvalumab; Medicine; Carboplatin; Tremelimumab; Tolerability; Internal medicine; Cisplatin; Oncology; Gemcitabine; Chemotherapy; Pembrolizumab; Cancer; Immunotherapy; Adverse effect; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005532762,0.0008053055,0.00190521,0.0003363444,0.0002690556,0.000773898,0.0008843109,0.0006439841,0.005297091],"category_scores_gemma":[0.0004106025,0.000405659,0.001301656,0.0004330397,0.0004383305,0.0006689834,0.0002861458,0.001914617,0.002079692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009560425,"about_ca_system_score_gemma":0.0012071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00252408,"about_ca_topic_score_gemma":0.007618397,"domain_scores_codex":[0.9997441,0.00009414915,0.00001549946,0.00004675528,0.00002907185,0.00007045591],"domain_scores_gemma":[0.9997701,0.00002490894,0.00003777857,0.0000241417,0.00001914141,0.0001238308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6356002,0.04629727,0.009351706,0.001948356,0.003089657,0.0002771713,0.0001409384,0.002253915,0.04562607,0.0004663577,0.01662699,0.2383213],"study_design_scores_gemma":[0.5752836,0.3768731,0.02982941,0.0001106222,0.001763997,0.000525213,0.00007385427,0.001602385,0.004606952,0.0002089183,0.009076862,0.00004507811],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791102,0.007448705,0.0003822915,0.0008693872,0.0002912034,0.002405211,0.003645516,0.0002295387,0.005617952],"genre_scores_gemma":[0.9762265,0.006338931,0.001342012,0.000986296,0.0002911859,0.001736486,0.006475366,0.00007025408,0.006532987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005297091,"threshold_uncertainty_score":0.01772052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0332512173496041,"score_gpt":0.4461936429016305,"score_spread":0.4129424255520264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}